3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
77
Pancreatic Neoplasms
56
Stomach Neoplasms
52
Rectal Neoplasms
43
Esophageal Squamous Cell Carcinoma
38
Esophageal Neoplasms
38
Neoplasm Metastasis
25
Colonic Neoplasms
23
Neoplasms
15
Cholangiocarcinoma
13
Liver Neoplasms
10
Gastrointestinal Neoplasms
10
Breast Neoplasms
9
Adenocarcinoma Of Esophagus
9
Carcinoma, Hepatocellular
7
Anus Neoplasms
7
Lung Neoplasms
6
Head and Neck Neoplasms
6
Biliary Tract Neoplasms
6
Ovarian Neoplasms
5
Melanoma
5
Adenocarcinoma
5
Kidney Neoplasms
4
Gastrointestinal Diseases
4
Digestive System Neoplasms
4
Carcinoma, Squamous Cell
4
Carcinoma, Non-Small-Cell Lung
4
Uterine Cervical Neoplasms
3
Sarcoma
3
Lymphoma
3
Interventions
Gemcitabine
6
Fluorouracil
5
Leucovorin
4
Irinotecan
3
Albumin-Bound Paclitaxel
3
pembrolizumab
2
irinotecan sucrosofate
2
Oxaliplatin
2
4-fluorobenzoyl-TN-14003
2
zolbetuximab
1
regorafenib
1
olaparib
1
ibrutinib
1
beta-D-glucosylisophosphoramide mustard
1
adavosertib
1
Tetrahydrouridine
1
Telemedicine
1
Taxes
1
Practice Guidelines as Topic
1
Paclitaxel
1
PEGPH20
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Docetaxel
1
Decitabine
1
Counseling
1
Cisplatin
1
Capecitabine
1
BKT140
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Pancreatic Adenocarcinoma
×
Drug Therapy
×
Gastrointestinal
×
Clear all
NCT02826486
2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2
Completed
80 enrolled
13 charts